Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 9/20 | 0.61 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.51 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.51 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.51 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.51 |
| ▸ | MAOA | P21397 | 2/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL536553 | 0.89 | MAOB (0.67) | MAOBCYP11B1CYP11B2CYP17A1CYP19A1 | |
| SCHEMBL669427 | 0.87 | CA2 (0.47) | MAOBMAOACA2 | |
| SCHEMBL30956093 | 0.85 | CA2 (0.46) | MAOBCA2 | |
| SCHEMBL293340 | 0.84 | MAOB (0.61) | MAOBCYP11B1CYP11B2CYP17A1CYP19A1 | |
| SCHEMBL12655257 | 0.83 | MAOB (0.73) | MAOBCYP11B1CYP11B2CYP17A1CYP19A1 | |
| SCHEMBL292377 | 0.83 | MAOB (0.59) | MAOBCYP11B1CYP11B2CYP17A1CYP19A1 | |
| SCHEMBL293945 | 0.83 | MAOB (0.63) | MAOBCYP11B1CYP11B2CYP17A1CYP19A1 | |
| SCHEMBL3799544 | 0.82 | CA2 (0.49) | MAOBCYP11B1CYP11B2CYP17A1CYP19A1 | |
| SCHEMBL18222923 | 0.80 | ALDH1A1 (0.56) | MAOBCYP19A1MAOACA12 | |
| SCHEMBL15397112 | 0.79 | ADORA2A (0.49) | MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1553911-B1 | 2-HETEROSUBSTITUTED 3-ARYL-4-H-1-BENZOPYRAN-4-ONES AS NOVEL THERAPEUTICS IN BREAST CANCER | UNIV OHIO STATE RES FOUND (US) | 2010-06-23 | — | — | EP | claimed |
| US-20060293321-A1 | 2-Heterosubstituted 3-aryl-4H-1-benzopyran-4-ones as novel therapeutics in breast cancer | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION | 2006-12-28 | — | — | US | claimed |
| US-7105542-B2 | 2-Heterosubstituted 3-aryl-4H-1-benzopyran-4-ones as novel therapeutics in breast cancer | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2006-09-12 | — | — | US | claimed |
| EP-1553911-A4 | 2-HETEROSUBSTITUTED 3-ARYL-4-H-1-BENZOPYRAN-4-ONES AS NOVEL THERAPEUTICS IN BREAST CANCER | UNIV OHIO STATE RES FOUND (US) | 2006-07-26 | — | — | EP | claimed |
| EP-1553911-A2 | 2-HETEROSUBSTITUTED 3-ARYL-4-H-1-BENZOPYRAN-4-ONES AS NOVEL THERAPEUTICS IN BREAST CANCER | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2005-07-20 | — | — | EP | claimed |
| US-20040087586-A1 | 2-Heterosubstituted 3-aryl-4H-1-benzopyran-4-ones as novel therapeutics in breast cancer | US ARMY, SECRETARY OF THE ARMY | 2004-05-06 | — | — | US | claimed |
| WO-2004012682-A2 | 2-HETEROSUBSTITUTED 3-ARYL-4-H-1-BENZOPYRAN-4-ONES AS NOVEL THERAPEUTICS IN BREAST CANCER | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2004-02-12 | — | — | WO | claimed |
| CN-113185486-B | Antitumor agent 3-aryl-4H-chromen-4-one for the treatment of cancer | 肯塔基大学研究基金会 | 2024-05-10 | — | — | CN | disclosed |
| CN-113185486-B | Antitumor agent 3-aryl-4H-chromen-4-one for the treatment of cancer | 肯塔基大学研究基金会 | 2024-05-10 | — | — | CN | disclosed |
| CN-113185486-B | Antitumor agent 3-aryl-4H-chromen-4-one for the treatment of cancer | 肯塔基大学研究基金会 | 2024-05-10 | — | — | CN | disclosed |
| CN-115974825-B | Method for preparing 3-substituted chromanone by metal-free catalytic hydrogenation | 中国科学院化学研究所 | 2024-03-05 | — | — | CN | disclosed |
| CN-115974825-A | Method for preparing 3-substituted chromanone through metal-free catalytic hydrogenation | 中国科学院化学研究所 | 2023-04-18 | — | — | CN | disclosed |
| CN-113185486-A | Antitumor 3-aryl-4H-chromen-4-ones for the treatment of cancer | 肯塔基大学研究基金会 | 2021-07-30 | — | — | CN | disclosed |
| WO-2004012682-A2 | 2-HETEROSUBSTITUTED 3-ARYL-4-H-1-BENZOPYRAN-4-ONES AS NOVEL THERAPEUTICS IN BREAST CANCER | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2004-02-12 | — | — | WO | disclosed |
| WO-2004012682-A2 | 2-HETEROSUBSTITUTED 3-ARYL-4-H-1-BENZOPYRAN-4-ONES AS NOVEL THERAPEUTICS IN BREAST CANCER | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2004-02-12 | — | — | WO | disclosed |
| EP-1033369-B1 | 5H-PYRANO [2,3-d:6,5-d']DIPYRIMIDINE DERIVATIVES HAVING AN ANTIBACTERIAL, ANTIVIRAL AND IMMUNO-MODULATING ACTIVITY | NATURAL DRUG SCIENCES L L C (US) | 2003-01-29 | — | — | EP | disclosed |
| US-6340755-B1 | IMMUNOMMODULATORS, BACTERICIDES AND VIRICIDES | NATURAL DRUG SCIENCES LLC | 2002-01-22 | — | — | US | disclosed |
| EP-1033369-A1 | 5H-PYRANO [2,3-d:6,5-d']DIPYRIMIDINE DERIVATIVES HAVING AN ANTIBACTERIAL, ANTIVIRAL AND IMMUNO-MODULATING ACTIVITY | Tets, Viktor Veniaminovich (RU) | 2000-09-06 | — | — | EP | disclosed |
| EP-0973516-A1 | USE OF HALO AND/OR NITRO-SUBSTITUTED FLAVONOIDS AS ANXYOLITICS | University of Strathclyde (GB) | 2000-01-26 | — | — | EP | disclosed |
| WO-1998044920-A1 | USE OF HALO AND/OR NITRO-SUBSTITUTED FLAVONOIDS AS ANXYOLITICS | UNIVERSITY OF STRATHCLYDE (GB) | 1998-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087586-A1 | 2-Heterosubstituted 3-aryl-4H-1-benzopyran-4-ones as novel therapeutics in breast cancer | CYP19A1, BRCA1, AHR | MAOB 1288/4885CYP11B1 358/4885CYP11B2 484/4885 |
| US-20060293321-A1 | 2-Heterosubstituted 3-aryl-4H-1-benzopyran-4-ones as novel therapeutics in breast cancer | CYP19A1, BRCA1, AHR | MAOB 1288/4885CYP11B1 358/4885CYP11B2 484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.